Lipoprotein(a) is Independently Associated with Polyvascular Disease Burden

J Atheroscler Thromb. 2026 Oct 7. doi: 10.5551/jat.66432. Online ahead of print.ABSTRACTAIMS: Lipoprotein(a) [Lp(a)] is an established, genetically determined risk factor for atherosclerotic cardiovascular disease. However, its association with the polyvascular disease burden remains unclear. This s

R Ryotaro Yamada

On the nature of GABAB receptors and their plasticity in the mammalian brain

Trends Neurosci. 2026 Sep 22:S0166-2236(26)00186-4. doi: 10.1016/j.tins.2026.09.004. Online ahead of print.ABSTRACTGamma-aminobutyric acid (GABA) is the principal inhibitory neurotransmitter of the mammalian CNS, essential for circuit function and behaviour. In the brain, GABA activates GABAA and GA

S Sam A Booker

Emerging biomarkers in cardiovascular disease

Adv Clin Chem. 2026;135:227-251. doi: 10.1016/bs.acc.2026.08.004. Epub 2026 Aug 31.ABSTRACTCardiovascular disease (CVD) is among the leading causes of morbidity and mortality worldwide. Advances in the development of novel diagnostic and therapeutic strategies are required to improve diagnostic accu

Z Zeeshan Ahmed

Modification of Clinical Practice to Minimize Environmental Impact

J Allergy Clin Immunol Pract. 2026 Oct;14(10):2179-2187. doi: 10.1016/j.jaip.2026.06.046.ABSTRACTAlthough the health care sector is dedicated to promoting health, it paradoxically contributes to climate change by burning fossil fuels, a major source of greenhouse gas emissions and air pollutants. It

S Susan E Pacheco

Fregoli syndrome in an adolescent with Moyamoya disease

BMJ Case Rep. 2026 Oct 7;19(10):e269907. doi: 10.1136/bcr-2025-269907.ABSTRACTMoyamoya disease (MMD) is a progressive cerebrovascular disorder characterised by distal internal carotid artery (ICA) stenosis and compensatory collateral vessel formation. Psychiatric manifestations are rare, particularl

N Nisha Rajan

Trajectory changes in psychosocial adaptation levels of patients after implantation of cardiac implantable electronic devices and development of the intervention programme: a mixed-methods research protocol

BMJ Open. 2026 Oct 7;16(10):e124197. doi: 10.1136/bmjopen-2026-124197.ABSTRACTINTRODUCTION: The implantation of cardiac implantable electronic devices (CIEDs) has become an important treatment for various types of arrhythmias and severe heart failure, effectively improving patient prognosis and incr

M Meirong Chen

Divergent Cardiac and Renal Outcomes by Systolic Blood Pressure in HFrEF

Am J Med. 2026 Oct 7:S0002-9343(26)00708-4. doi: 10.1016/j.amjmed.2026.09.038. Online ahead of print.ABSTRACTBACKGROUND: Elevated systolic blood pressure (SBP) is associated with paradoxically lower mortality in heart failure with reduced ejection fraction (HFrEF), but whether this reflects underlyi

H Helen M Sheriff